Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of its lung drugs has turned out positive study data that show its non-inferiority to Glaxo's top seller in COPD, and with its more convenient dosing regimen, it could prompt patients on Advair to make the switch.
Going well beyond the standard sponsor-CRO relationship, Biogen Idec has recruited Quintiles to revamp its clinical development process, giving the contractor a seat at the R&D table to improve trial efficiency.
AstraZeneca is continuing its campaign to refashion its image as it tries to shake off past setbacks and unsuccessful units and turn analysts' attention to its brightest pipeline prospects, particularly in cancer.
A hybrid international biotech upstart with deep U.S. academic roots, a company base in Basel and a plan to grow its research operations in London has landed a $25 million A round to launch another effort at gene editing using CRISPR/Cas9 technology--one of the hottest emerging fields in drug development.
The big trend in Big Pharma R&D has been to cut back significantly in key areas where they felt they faced extraordinarily high risks--a particular problem in the central nervous system field, where trial failures have been more the norm than the exception.
Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.
Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.
Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.
Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.
Zafgen has been turning heads with some jaw-dropping results from its mid-stage studies for a promising new obesity drug. And now the biotech hopes to parlay its eye-catching, if risky, technology into an $86 million IPO.